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Abstract
Aldehyde dehydrogenase isoform 1 (ALDH1) has been proved useful for the identification of cancer stem cells. However, our
knowledge of the expression and activity of ALDH1 in common epithelial cancers and their corresponding normal tissues is
still largely absent. Therefore, we characterized ALDH1 expression in 24 types of normal tissues and a large collection of
epithelial tumor specimens (six cancer types, n=792) by immunohistochemical staining. Using the ALDEFUOR assay, ALDH1
activity was also examined in 16 primary tumor specimens and 43 established epithelial cancer cell lines. In addition, an
ovarian cancer transgenic mouse model and 7 murine ovarian cancer cell lines were analyzed. We found that the expression
levels and patterns of ALDH1 in epithelial cancers are remarkably distinct, and they correlate with their corresponding
normal tissues. ALDH1 protein expression levels are positively correlated with ALDH1 enzymatic activity measured by
ALDEFLUOR assay. Long-term in vitro culture doesn’t significantly affect ALDH1 activity in epithelial tumor cells. Consistent
with research on other cancers, we found that high ALDH1 expression is significantly associated with poor clinical outcomes
in serous ovarian cancer patients (n=439, p=0.0036). Finally, ALDH
br tumor cells exhibit cancer stem cell properties and are
resistant to chemotherapy. As a novel cancer stem cell marker, ALDH1 can be used for tumors whose corresponding normal
tissues express ALDH1 in relatively restricted or limited levels such as breast, lung, ovarian or colon cancer.
Citation: Deng S, Yang X, Lassus H, Liang S, Kaur S, et al. (2010) Distinct Expression Levels and Patterns of Stem Cell Marker, Aldehyde Dehydrogenase Isoform 1
(ALDH1), in Human Epithelial Cancers. PLoS ONE 5(4): e10277. doi:10.1371/journal.pone.0010277
Editor: Yihai Cao, Karolinska Institutet, Sweden
Received December 1, 2009; Accepted March 30, 2010; Published April 21, 2010
Copyright:  2010 Deng et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants from the Breast Cancer Alliance (LZ), the Ovarian Cancer Research Found (Liz Tilberis Scholar, LZ), the Mary Kay Ash
Charitable Foundation (LZ), National Cancer Institute (R01CA142776 and Ovarian Cancer SPORE P50-CA83638-7951 project 3, LZ), and US Department of Defense
(W81XWH-10-1-0082, LZ). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: linzhang@mail.med.upenn.edu
. These authors contributed equally to this work.
Introduction
Research has provided strong support for the cancer stem cell
hypothesis, which proposes that a relatively rare subpopulation of
tumor cells have the unique ability to initiate and perpetuate tumor
growth [1,2,3,4,5,6,7,8,9,10]. These cells, called cancer stem cells or
tumor-initiating cells, share various characteristics with embryonic
and somatic stem cells including self-renewal and multi-potent
differentiation [11,12,13,14,15,16,17]. Cancer stem cells may be
highly resistant to radiation or chemotherapy [18,19,20], therefore,
the development of more effective therapies for cancer requires
effective targeting of this cell population [11,12,13,14,15,16,17].
Cancer stem cells can be identified and isolated using markers specific
for normal progenitor or stem cells of the sameorgan [16,21]. Several
markers have proved useful for the isolation of subsets enriched for
epithelial cancer stem cells, including CD44/CD24 (HAS/PGP1)
[3], CD133 (PROM1) [4], ATP-binding cassette B5 (ABCB5) [22],
CD90 (THY1) [23], CD61(b3 Integrin) [24], 26S proteasomeactivity
[25], as well as Hoechst33342 exclusion [6,26,27].
Aldehyde dehydrogenase (ALDH) catalyzes the irreversible
oxidation of a range of aliphatic and aromatic aldehydes to their
corresponding carboxylic acids [28]. High ALDH activity is
detected in stem and progenitor cells of various lineages including
hematopoietic [29,30,31], mesenchymal [32], neural [33], mam-
mary [34,35] and prostate [36]. The ALDEFLUOR assay was
originally developed to detect ALDH activity in hematopoietic
tissues; the fluorescent ALDEFLUOR reaction product accumu-
lates in stem cells and correlates with ALDH activity [29]. ALDH
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hyde), into the fluorescent product BAA (BODIPY-aminoacetate),
which is retained inside viable cells. Cells expressing high levels of
ALDH become brightly fluorescent (ALDH
br) and can be identified
and enumerated using a standard flow cytometer or isolated by cell
sorting for further purification and characterization. ALDE-
COUNTH is an FDA-approved in vitro diagnostic product which
is based on the ALDEFLUOR assay and is used for the
identificationand enumeration of stem cells for clinical applications.
Most recently, the ALDEFLUOR assay has been successfully
applied to detect the progenitor and cancer stem cells in non-
hematopoietic tissues such as mammary gland and breast cancers
[34]. The ALDEFLUOR reagent is known to act as a substrate for
ALDH1. Importantly, an ALDH1 specific antibody can be used to
detect cancer stem cells in paraffin-embedded clinical specimens
[34]. Several independent groups have reported that ALDH1
expression can be used as a prognostic marker for epithelial cancers
[34,37,38,39,40,41,42,43]. Therefore, the ALDEFLUOR assay
and ALDH1 immunostaining may prove useful for the detection
and isolation of cancer stem cells in epithelial tumors, thus
facilitating the introduction of cancer stem cell concepts to clinical
practice [34]. However, our knowledge of the expression and
activity of ALDH1 in human epithelial cancers and their
corresponding normal tissues, as well as its clinical significance, is
still in its infancy. To advance our knowledge in this important area,
we characterized ALDH1 expression in 24 types of normal human
tissues as well as a large collection of paraffin-embedded human
epithelial tumor specimens (six cancer types, n=792) by immuno-
histochemical staining. Using the ALDEFUOR assay, ALDH1
activity was also examined in 16 primary tumor specimens and 43
established human epithelial cancer cell lines. In addition, an
ovarian cancer transgenic mouse model and 7 murine ovarian
cancer cell lines were analyzed in our study.
Materials and Methods
Fresh Tumor Specimens
Tissues were obtained after patients’ written consent under a
general tissue collection protocol approved by the institution’s
Institutional Review Board (IRB) of the University of Pennsylva-
nia. All specimens were collected at the time of debulking surgery
from previously untreated patients with late-stage ovarian cancer.
Erythrocytes were lysed with ammonium chloride solution. Single-
cell suspensions were prepared using a 40 mm cell strainer. Dead
cells were eliminated using magnetic beads (Dead Cell Removal
kit, Miltenyi Biotec) and a MidiMACS separator.
Tissue microarrays
Tissue array network cohort: An FDA normal human organ tissue
microarray was used to characterize ALDH1 expression in normal
organs. This tissue array platform included 24 types of normal
human organs based on FDA guidelines, and each organ was
sampled from 3 normal individuals. Six types of human epithelial
tumor tissue microarrays were used to characterize ALDH1
expression in epithelial tumors. Each patient was represented with
at least two core tissue biopsies. Helsinki cohort: An ovarian cancer
tissue microarray was used to examine the prognostic significance
of ALDH1 in ovarian cancer. The array included patients treated
for primary serous ovarian carcinoma at the Helsinki University
Central Hospital.
Cell lines and Cell Culture
A total of 50 established cancer cell lines were used in this study
including 15 human breast, 18 human ovarian, 7 murine ovarian,
and 10 human colon. All cancer cell lines were cultured in RPMI
1640 medium supplemented with 10% fetal bovine serum
(Invitrogen). Three independent immortalized human ovarian
surface epithelial cells (IOSEs) were generously provided by Dr.
Auersperg, and cultured in a 1:1 combination of medium 199 and
MCDB 105 medium (Sigma) supplemented with 15% FBS.
Murine ovarian surface epithelial cells (MOSEs) were isolated and
cultured as previously reported [44].
Transgenic Mice
The animal study protocol was reviewed and approved by the
institutional animal care and use committee (IACUC) of the
University of Pennsylvania. The ovarian cancer MISRII-SV40
transgenic mouse was generated by Dr. Denise Connolly’s
laboratory [45].
Immunohistochemistry and Image Analysis
Immunohistochemistry (IHC) was performed using the VEC-
TASTAIN ABC Kit as described by the manufacturer (Vector).
The following primary antibodies were used in this study: mouse
anti-human ALDH1 (clone: 44/ALDH, 1:250, BD Pharmingen)
[34,39,46]; mouse anti-human Ki67 (1:100, DAKO) and rabbit
anti-human CD45 (1:200, Millipore). Antibodies were incubated
overnight at 4uC. The immunoreaction was visualized with 3,39-
diaminobenzidine. Double immunofluorescent staining was per-
formed as previously described [47].
ALDEFLUOR Assay
ALDH activity was detected using the ALDEFLUOR assay kit
(StemCell Technologies) as described by the manufacturer. Briefly,
dissociated single cells from cell lines or tumor specimens were
suspended in ALDEFLUOR assay buffer containing an ALDH
substrate, bodipy-aminoacetaldehyde (BAAA), at 1.5 mM, and incu-
bated for 1 hr at 37uC. A specific inhibitor of ALDH, diethylamino-
benzaldehyde (DEAB), at a 10-fold molar excess, was used as negative
control. Flow cytometry data was analyzed by BD FACSDiva software
V6.1.3 (BD Biosciences) or FlowJo software (TreeStar).
Protein Isolation and Western blot
Cultured cells were lysed in 200 ml of lysis buffer containing
50 mM Tris-HCl (pH 7.4), 150 mM NaCl, and 1% Triton X-100.
Proteins were separated by 10% SDS-PAGE under denaturing
conditions and transferred to nitrocellulose membranes. Membranes
were incubated with an anti-ALDH1 primary antibody (1:300, BD
Pharmingen), followed by incubation in anti-mouse secondary
antibody conjugated with horseradish peroxidase (1:5,000; Amer-
sham Biosciences). Immunoreactive proteins were visualized using
ECL Western Blotting Substrate (Thermo Scientific).
Mammosphere culture
Mammosphere cultures were performed as described by Dontu et
al [48]. Briefly, single cells were plated in ultra-low attachment 24-
well plates (Corning) at a density of 20,000 viable cells/ml and 5000
cells/ml in subsequent passages. Cells were grown in a serum-free
mammosphere culture medium (MammoCult, StemCell Technol-
ogies) supplemented with MammoCult Proliferation Supplements.
Mammospheres were collected by gentle centrifugation (800 rpm)
after 7–10 days and dissociated both mechanically and enzymat-
ically (10 min in 0.05% trypsin, 0.53 mM EDTA-4Na).
In vivo tumorigenic assay
The animal study protocol was reviewed and approved by the
institutional animal care and use committee (IACUC) of the
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deficient mice were used in these studies. ALDH
low and ALDH
br
(ALDH
bright) cells were isolated by FACS sorting. Cells were
suspended in phosphate buffered saline mixed with an equal
volume of Matrigel (BD Biosciences) at 10 mg/ml. A total volume
of 0.3 ml, containing 500; 5,000 or 50,000 cells, was injected
subcutaneously (ovariectomized and oestrogen-pellet supplement-
ed mice).
MTT assay
MTT assays were performed in 96-well plates using the Cell
Proliferation Kit (I) (Roche) following the manufacturer’s instruc-
tions.
Statistical analysis
Statistical analysis was performed using the SPSS and StatView
statistical software packages.
Results
Expression and distribution of ALDH1 protein in normal
human tissues
As a stem cell marker, ALDH1 has been used to detect cancer
stem cells in multiple types of human epithelial tumors using
immunohistochemical staining; however, its expression and
distribution patterns in normal human tissues are still largely
unknown. To address this important question, we characterized
the expression pattern of ALDH1 in normal human tissues by
immunohistochemical staining. An FDA-approved normal human
organ tissue microarray was used in this study. Here, 24 types of
normal human organs were included based on FDA guidelines,
where each organ was taken from 3 normal human individuals.
Mouse anti-human ALDH1 antibody (clone: 44/ALDH)
[34,39,46] was used to detect ALDH1 expression. As shown in
Figure 1A, ALDH1 positive staining was detected mainly in the
cytoplasm, and was widely expressed in the digestive system
(including the epithelium of the esophagus, stomach, intestine and
colon, as well as the liver and pancreas), the endocrine system
(including the adrenal gland, hypophysis, thyroid and salivary
gland) and the reproductive system (ovary and testis). There were
no detectable ALDH1 positive cells in the cerebrum and
cerebellum (Figure 1A). In other organs, ALDH1 was distributed
in certain areas and in specific cell types. For example, in the
spleen, ALDH1 positive cells were mainly found in leukocytes of
the red pulp regions, but not in the white pulp (Figure 1A).
Importantly, consistent with other reports [34,46,49], strongly
ALDH1 positive cells were found in the areas in which epithelial
stem/progenitor cells were putatively located in the breast, colon
and stomach (Figure 1B). In normal breast, ALDH1 positive cells
were mainly located in the luminal region (Figure 1B), and they
were a relatively rare population (1–2% of luminal epithelial cells).
Small ALDH1 positive cells were also found in normal breast
Figure 1. Expression and distribution of ALDH1 protein in normal human tissues. A. An FDA normal human organ tissue microarray was
used to characterize the expression and distribution of ALDH1 in 24 tissues. B. Strongly positive ALDH1 cells were found in the areas in which
epithelial stem/progenitor cells were putatively located in breast, colon and stomach.
doi:10.1371/journal.pone.0010277.g001
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demonstrated that most of these cells (.90%) were CD45 positive
leukocytes (data not shown). In the normal colon, although weakly
ALDH1 positive cells could be found in nearly all normal crypts,
the number of strongly positive ALDH1 cells was quite limited
(Figure 1B). These strongly positive cells were mainly located at
the bases of the crypts (Figure 1B). Similar staining patterns are
also seen in the stomach (Figure 1B).
Expression and distribution of ALDH1 protein in human
epithelial tumors
Next, we investigated ALDH1 expression in human epithelial
tumors using tissue arrays. As shown above, the patterns and levels
of expression of ALDH1 in normal human tissues are remarkably
different and can be classified into three types: 1) tissue with absent
or limited ALDH1 expression, such as breast or lung; 2) tissue with
relative weak ALDH1 expression, such as colon or gastric
epithelium; and 3) tissue with extensive and high expression of
ALDH1 such, as liver or pancreas (Figure 1A). Thus, we chose six
types (breast, n=69; lung, n=66; ovarian, n=65; colon, n=67;
liver, n=67; and pancreatic cancer, n=19) of epithelial cancers
whose corresponding normal epitheliums were representative of
each subtype. In all six tumor types, a large number of ALDH1
positive tumor-infiltrating stromal cells were found (Figure 2B).
Double immunostaining demonstrated that most of these were
CD45 positive cells. The percentage of ALDH1 positive tumor
cells in tumor islets was independently quantified by two
investigators with pathological training. Stromal ALDH1 positive
cells were excluded from this analysis. We found that ALDH1
expression was negative in 79.7% (55/69) of breast, 18.2% (12/66)
of lung and 23.1% (15/65) of ovarian cancers. On the contrary,
only 6.0% (4/67) of colon and 5.3% (1/19) of pancreatic cancers
were ALDH1 negative, and all liver cancer specimens were
ALDH1 positive. In addition, for those ALDH positive tumors, the
percentage of tumor cells expressing ALDH1 was also analyzed.
The detailed percentage of ALDH1 positive cancer cells is
summarized in Figure 2C. Except in the case of breast cancer
(4.3%), a high percentage of ALDH1 expression (between 75 to
100% of tumor cells) was found in each of the other five cancer
types (ovarian: 29.2%, colon: 38.8%, lung: 43.9%, pancreatic
78.9% and liver: 97.0%). Taken together, there was a clear
correlation of ALDH1 expression between tumors and corre-
sponding normal tissues. For example, in those cancer types where
ALDH1 was highly expressed in the corresponding normal
epitheliums, such as liver and pancreatic cancers, ALDH1 was
expressed in most tumor specimens at remarkably high levels.
It has been reported by independent groups that a high
percentage of ALDH1 positive tumor cells is associated with
shorter survival times in breast [34,37,42], lung [38], pancreatic
[40], bladder [41] and prostate [43] cancer patients. We tested the
prognostic value of ALDH1 using a tissue array of serous ovarian
cancers, the most common histotype of human epithelial ovarian
cancer. The specimens were collected from the Department of
Gynecology and Obstetrics at the Helsinki University Central
Hospital. The median follow-up time of patients alive at the end of
the study period was 101 months, ranging from 4 to 475 months.
The patients were separated into two groups based on ALDH1
immunostaining: ALDH1 low (,10% tumor cells were ALDH1
positive) and ALDH1 high ($10% tumor cells were ALDH1
positive). Consistent with the results from breast [34,37,42], lung
[38], pancreatic [40], bladder [41] and prostate [43] cancer
patients, we found that patients with high ALDH1 had shorter
disease free and overall survival times compared to those with low
ALDH1 (p=0.0036 and p=0.023, respectively, Figure 2D).
ALDH1 enzymatic activity in epithelial tumor cells
The ALDEFLUOR reagent, originally developed to detect
ALDH activity in hematopoietic tissues [29], is known to act as a
substrate for ALDH1. Recently, the ALDEFLUOR assay has
been successfully applied to detect ALDH
br in cancer stem cells
from non-hematopoietic tumors [34]. In the present study, we
utilized this assay to examine ALDH1 enzymatic activity in
epithelial tumor cells in vitro. First, to validate the results of the
tissue array, we chose cell lines from three epithelial tumor types
including breast (n=15), ovarian (n=18) and colon (n=10). As
shown in Figure 2, the percentage of tumors with a high frequency
of ALDH1 positive cells was greater in colon cancer compared to
breast or ovarian cancer. Consistent with this finding, we found
that the percentage of ALDH
br cells in colon cancer cell lines
(15.5611.5%) was remarkably higher than in breast (3.564.8%)
or ovarian (6.2613.5%) cancer cell lines (Figure 3B and Table S1).
To further confirm this result, we detected ALDH1 protein
expression by western blots in these cell lines. As expected,
ALDH1 protein expression levels were positively correlated with
the percentage of ALDH
br cells in the cell lines (Figure 3C and
Figure S3). Although there was a clear positive correlation
between in situ immunostaining and the ALDEFLUOR assay
results in these three tumor types, the percentage of cells exhibiting
ALDH1 enzymatic activity by flow cytometry was smaller than the
percentage of ALDH1 positive cells by immunostaining. For
example, 4.3%, 29.2% and 38.8% of breast, ovarian and colon
cancer specimens highly expressed ALDH1 (between 75 to 100%
of tumor cells were ALDH1 positive, Figure 2C), however, none of
the tumor cell lines were composed of greater than 75% of
ALDH
br cells (Table S1). Next, we chose ovarian cancer as an
example to investigate the ALDH enzymatic activity in primary
tumor cells. Sixteen late stage ovarian cancer specimens were
examined. Since we found that tumor-infiltrating leukocytes
expressed high levels of ALDH1 (Figure 2B), we first separated
ascites cells by CD326 (EpCAM, an epithelial marker to gate the
tumor cell population) or CD45 (a lymphocyte maker to gate
lymphocyte population) after removing dead cells using magnetic
beads. The ALDEFLUOR assay was used to detect cells with
ALDH activity in each of above population (Figure 4A). We found
that 2.663.1% (0.1–11.3%) of CD45 positive cells were ALDH
br
(Figure 4B). Consistent with the cell line study, 1.161.9% (0.1–
7.0%) of CD326 positive tumor cells were ALDH
br (Figure 4B), a
lower percentage than in the immunostaining results.
To address the question whether long-term in vitro culture will
significantly affect ALDH activity in cancer cell lines, we chose an
ovarian cancer transgenic mouse model, in which an oncogene
(the transforming region of SV40) was overexpressed by the
ovarian surface specific Mu ¨llerian inhibiting substance type II
receptor (MISRII) promoter (Figure S1A). The ALDEFLUOR
assay was performed on both primary isolated tumor cells and two
long-term cultures of tumor cell lines (more than 40 passages) that
were isolated from the same model. We found that there was no
significant difference in the percentage of ALDH
br cells between
primary tumors (9.567.6%, n=5) and long-term cell cultures
(6.864.9%, n=2, P.0.05, Figure S1B). Since only limited
numbers of cell lines were analyzed in the present study, this
conclusion need further validate in other models.
Finally, we compared ALDH activity in ovarian cancer cells and
their corresponding normal epitheliums, ovarian surface epithelial
cells. Three immortalized human ovarian surface epithelial cell
lines were compared to 18 human ovarian cancer cell lines, and
primary isolated murine ovarian surface cells were compared to 7
murine ovarian cancer cell lines (including two lines from the
MISIIR-SV40 transgenic mouse). We found that the percentage of
ALDH1 in Epithelial Cancers
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br cells was relatively higher in normal ovarian surface
epithelial cells (human: 13.166.72%, n=3; murine: 7.6%, n=1)
compared to ovarian cancer cells (human: 6.2613.5%, n=18;
murine: 3.862.92%, Figure S2). Similarly, the percentage of
ALDH
br cells was relatively higher in normal mammary epithelial
cells (8.1864.31%, n=14) [34] compared to breast cancer cells
(3.564.8%, n=15, Figure 3).
ALDH
br tumor cells have cancer stem cell properties and
are resisted to chemotherapy
It has been demonstrated that ALDH
br tumor cells isolated
from primary human tumors or from short-term passages of cells
from NOD/SCID mice have cancer stem cell properties [34] and
are resistant to chemotherapy [50,51]. To examine the cancer
stem cell properties of ALDH
br cells isolated from established
Figure 2. Expression and distribution of ALDH1 protein in human epithelial tumors. Tissue microarrays were used to characterize the
expression and distribution of ALDH1 in cancers (n=353). A. Expression of ALDH1 in the corresponding normal tissues. B. ALDH1+ tumor-infiltrating
cells were detected in the stroma. C. Expression of ALDH1 in epithelial tumors. Percentage of ALDH1+ tumor cells was summarized. D. High
percentage of ALDH1+ cells was associated with poor clinical outcomes in serous ovarian cancer.
doi:10.1371/journal.pone.0010277.g002
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low and ALDH
br tumor cells
were isolated from established human breast and ovarian cancer
cell lines by FACS sorting. First, their self-renewal ability was
examined using the mammosphere assay [48] in four breast cancer
cells. The number of mammospheres formed by ALDH
br tumor
cells was significantly higher than by ALDH
low tumor cells
(Figure 5A). ALDH
low cells from T47-D and ZR-75-1 cell lines
lacked the ability to form mammospheres in suspension culture.
Next, we examined their in vitro tumor growth capabilities using
the colony formation assay in 5 breast cancer cell lines. ALDH
br
tumor cells formed visibly larger colonies compared to ALDH
low
tumor cells (Figure 5B). In addition, the colony numbers from
ALDH
br tumor cells were significantly higher than from ALDH
low
tumor cells (Figure 5B). Finally, the in vivo tumorigenic ability of
the ALDH
low and ALDH
br tumor cells was examined using tumor
cells that were graft-transplanted (500; 5,000; or 50,000) to
immune deficient mice. We found that 500 ALDH
br but not
ALDH
low tumor cells were capable of generating xenograft tumors
in vivo (Figure 5C). Histology of three xenograft tumors was
examined by HE staining. In MCF-7 and SKBR-3 cell lines, there
was no significant histological difference between ALDH
br and
ALDH
low tumors. However, in BT-474 tumors, there were limited
stromal cells in ALDH
br tumors compared to ALDH
low tumors
(Figure 5D). In vivo cell proliferation was also examined using Ki-
67 staining. We did not find any significant difference in the
proliferation index (percentage of Ki-67 positive cells) between the
ALDH
br and ALDH
low tumors in all three cell lines (Figure 5E).
Rapidly accumulating evidence suggests that cancer stem cells
may be highly resistant to radiation or chemotherapy [18,19,20].
Consistent with these findings, we found that the ALDH
br cell
population is expanded in a set of platinum resistant ovarian
cancer cell lines, A2780/CP70, A2780/C200 and A2780/C30,
compared to their parental platinum sensitive line, A2780/WT
(Figure 6A). Furthermore, treatment of cells with cisplatinum
(1XIC50) significantly enriched the ALDH
br cell population in
ovarian and breast cancer cell lines in vitro (Figure 6B). The
ALDH
br population was significantly more resistant to platinum
treatment compared to the ALDH
low population (Figure 6C).
Lastly, we test the above observation in vivo using an ovarian
cancer xenograft mouse model. Three weeks after the implanta-
tion of tumor cells, A2780 (5610
6 per animal), the mice were
randomly assigned to three experimental groups to receive
treatment by i.p. injection with 1) control treatment (n=4), 2)
2 mg/kg cis-platinum treatment (K maximum tolerated dose
(MTD), n=3) and 3) 4 mg/kg cis-platinum treatment (full MTD,
n=3). The q7d64 i.p. treatment schedule (Figure 6D) was used
for the experimental therapy. Percentage of the ALDH positive
population was analyzed by ALDEFLUOR assay. Consistent with
Figure 3. ALDH1 enzymatic activity and expression in established epithelial tumor cell lines. A. ALDH1 enzymatic activity was detected
using the ALDEFLUOR assay. DEAB was used to inhibit the reaction of ALDH with the ALDEFLUOR reagent, providing a negative control. B. Summary
of ALDH1 enzymatic activity in established breast (n=15), ovarian (n=18) and colon (n=10) cancer cell lines. C. ALDH1 protein expression was
detected by western blots. There was a positive correlation between ALDH1 protein expression and ALDH1 enzymatic activity. Full-length blots are
presented in Supplemental Figure S3.
doi:10.1371/journal.pone.0010277.g003
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ALDH
br cell population in xenograft tumor in vitro (Figure 6D, K
MTD: 8.44-fold in average; full MTD: 4.67-fold in average,
compared to non-treated tumors). It suggests that ALDH
br tumor
cell population is resistant to chemotherapy. Similar results was
also reported in colon cancer in vivo most recently by an
independent group [50].
Discussion
As a novel approach, the ALDEFLUOR assay and ALDH1
immunostaining may prove useful for the detection and isolation
of cancer stem cells in epithelial tumors, thus facilitating the
application of cancer stem cell concepts to clinical practice [34].
We found that pattern and level of expression of ALDH1 in
normal human tissues are remarkably different and could be
classified into three types: 1) tissue with absent or limited ALDH1
expression, such as breast or lung; 2) tissue with relative weak
ALDH1 expression, such as colon or gastric epitheliums; and 3)
tissue with extensive and high expression of ALDH1, such as liver
or pancreas (Figure 1A). In agreement with other reports
[34,46,49], we found that strongly positive ALDH1 cells can be
clearly identified in regions where epithelial stem/progenitor cells
are putatively located in the first two types of tissues (Figure 1B).
Ginestier et al. has demonstrated that these ALDH1 positive cells
are indeed epithelial progenitor cells [34]. Taken together,
ALDH1 can serve as a marker to detect stem/progenitor cells in
situ in those tissues where ALDH1 expression is limited (such as
breast) or weak (such as colon). However, for the tissues with wide
and strong expression of ALDH1 (such as liver and pancreas),
ALDH1 may not be able to be serve as a stem cell marker.
Importantly, we found that the percentage of ALDH1 positive
tumor cells was significantly correlated with the level of ALDH1
expression in corresponding normal tissues. For example, ALDH1
Figure 4. ALDH1 enzymatic activity in primary epithelial ovarian cancer cells. A. ALDH1 enzymatic activity in cells isolated from one
ovarian cancer specimen. Dead cells were eliminated using magnetic beads and a MidiMACS separator. For immunophenotyping of ALDH
br ascites
cells, APC-CD45 or APC-CD326 was used for counterstaining. DEAB was used to inhibit the reaction of ALDH with the ALDEFLUOR reagent, providing
a negative control. B. Summary of the percentages of ALDH
br in each cell population from 16 late-stage ovarian cancer patients.
doi:10.1371/journal.pone.0010277.g004
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In each of these cancer types, the percentage of ALDH1 negative
tumor cells was significantly larger than in colon cancer, whose
corresponding tissue, colon epithelium, expressed relatively higher
ALDH1 (Figure 2). Furthermore, in other two types of cancers
examined in our study, liver and pancreas, almost all tumor cells
were ALDH1 positive, while the corresponding normal tissues
expressed extensive, high levels of ALDH1 (Figure 2). This finding
was further confirmed in vitro by the ALDEFUOR assay. Tumor
cells derived from tumors exhibiting high ALDH1 levels contained
a significantly higher frequency of ALDH
br cells compared to
tumors expression low ALDH1 levels (Figure 3 A and B). These
results indicate that as a cancer stem cell marker, ALDH1 may be
only suitable for those tumors whose corresponding normal tissues
express a low background level of ALDH1. Finally, increasing
evidence indicates that higher percentage of ALDH1 positive
tumor cells may serve as a novel prognostic marker associated with
poor clinical outcome in multiple human solid cancers including
breast [34,37,42], lung [38], pancreatic [40], bladder [41] and
prostate [43] cancers. Meanwhile, Chang et al. have reported the
ALDH1 expression correlates with favorable prognosis in ovarian
cancer including 266 serous ovarian cancer patients and 176 non-
serous ovarian cancer patients [39]. Consistent with the reports in
multiple types of tumors [34,37,38,40,41,42,43], we found that
higher percentage of ALDH1 positive tumor cells is significantly
associated with poor clinical outcome in serous ovarian cancer
(Figure 2D, n=439, p=0.0036). It indicates that the prognostic
value of ALDH1 in ovarian cancer, albeit potent, may well be
histotype-type specific. Based on clinicopathological and molecular
studies, different histotype ovarian epithelial tumors have
remarkably distinct molecular background and biological behav-
ior. They may be considered as different diseases, although they
are located in the same anatomic location. Therefore, the
prognostic value of ALDH1 in different types of ovarian cancers
Figure 5. ALDH
br tumor cells exhibit cancer stem cell properties. A. ALDH
br cell populations (Blue) generated significantly higher numbers
of mammospheres compared to the ALDH
low population (Yellow). B. Tumorigenicity of the ALDH
br and ALDH
low cells were examined in vitro
using colony formation assays. C. Tumorigenicity of the ALDH
br and ALDH
low cells were examined in vivo. D. Histology of the ALDH
br and
ALDH
low BT-474 tumors was examined by HE staining. E. Proliferation of the ALDH
br and ALDH
low BT-474 tumors was examined by Ki-67
immunostaining.
doi:10.1371/journal.pone.0010277.g005
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sample sets.
Using the ALDEFLUOR assay, we examined ALDH1 enzy-
matic activity in both established and primary cancer cell lines. We
found that ALDH1 enzymatic activitywaspositively correlatedwith
ALDH1 expression in cancer cells (Figure 3C). Although we found
that ALDH1 activity was relatively higher in the established ovarian
cancer cell lines compared to primary ovarian tumor specimens
(Figure 3B and Figure 4B), we did not find a significant difference in
ALDH1 activity between primary isolated tumors and long-term
cultures of tumor cell lines from the same ovarian cancer transgenic
mousemodel(FigureS1),suggesting thattherelativelylowerALDH
enzymatic activity observed in primary ovarian cancer cells may be
due to the procedure of sample collection and preparation.
Interestingly, we found that the ALDH1 enzymatic activity was
relatively lower in ovarian cancer cell lines compared to normal
ovarian surface epithelial cells (Figure S2). Similar results were also
found in breast cancer [34].
It has been demonstrated that ALDH
br tumor cells isolated
from primary tumors have cancer stem cell properties such as self-
renewal and tumorigenicity [34]. In the present study, we
examined these properties in the ALDH
br cells isolated from
established tumor cell lines. Similar to the results based on primary
tumors [34], ALDH
br tumor cells from breast cancer cell lines
generated a significantly higher number of tumorspheres in vitro,
and were more tumorigenic in vitro and in vivo (Figure 5). In
agreement with our findings, several groups also reported that
ALDH
br cell populations isolated from established cancer cell lines
had more tumorigenic and metastatic capacities [42,52,53]
Finally, we demonstrated that ALDH
br ovarian cancer cells were
resistant to chemotherapeutic drugs such as platinum (Figure 6).
Both long-term and short-term platinum treatments led to an
enrichment of the ALDH
br tumor cell population. This result is
consistent with findings in other cancers [50,51], and indicates that
the development of more effective therapies for cancer requires
effective targeting of this cell population.
Supporting Information
Table S1 Summary of percentage of ALDH bright cells in cell
lines (n=54).
Found at: doi:10.1371/journal.pone.0010277.s001 (0.09 MB
DOC)
Figure S1 ALDH1 enzymatic activity in murine primary
ovarian cancer cells and long-term cultured cell lines from a
transgenic animal. A. An ovarian cancer transgenic mouse model
expressing the transforming region of SV40 under control of the
MISRII promoter was used in this study. Bilateral ovarian tumors
developed at 15,17 weeks post birth. B. Summary of the
percentage of ALDHbr cells in primary ovarian cancer cells and
long-term cultured cell lines from same tumor model.
Found at: doi:10.1371/journal.pone.0010277.s002 (0.22 MB
TIF)
Figure S2 ALDH1 enzymatic activity in ovarian surface
epithelial cells and epithelial ovarian caner cell lines. Summary
of the percentage of ALDHbr cells in human (left) and murine
(right) ovarian surface epithelial cells and epithelial ovarian caner
cell lines.
Found at: doi:10.1371/journal.pone.0010277.s003 (0.17 MB
TIF)
Figure S3 Full-length blots of figure 3C.
Figure 6. ALDH
br tumor cells are resistant to the chemotherapeutic drug platinum. A. ALDH
br cells were remarkably expanded in platinum
resistant cell lines (A2780/CP70, A2780/C200 and A2780/C30) compared to their parental platinum sensitive line (A2780/WT). B. In vitro platinum
treatment significantly increased the ALDH
br cell population in ovarian and breast cancer cell lines after three days. C. ALDH
br cells were resistant to
platinum treatment. ALDH
br and ALDH
low cells were isolated by FACS sorting. D. ALDH
br tumor cell population was resistant to chemotherapy in vivo.
The q7d64 i.p. treatment schedule was used for the experimental therapy. Tumors were collected and disassociated by enzyme digestion.
Percentage of the ALDH
br population was analyzed by ALDEFLUOR assay.
doi:10.1371/journal.pone.0010277.g006
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